Elimination of the differential chemoresistance between the murine B-cell lymphoma LY-ar and LY-as cell lines after arsenic (As2O3) exposure via the overexpression of gsto1 (p28)

Cancer Chemotherapy and Pharmacology

Volumn 55, Issue 6, 2005, Pages 511-521

  Giri, U ^a   Terry, N H A ^a   Kala, S V ^b   Lieberman, M W ^b   Story, M D ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Apoptosis; Arsenic trioxide; Cell survival; Glutathione S transferase omega; GSH

Indexed keywords

ARSENIC; ARSENIC DERIVATIVE; ARSENIC TRIOXIDE; CISPLATIN; CYSTEINE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; GLUTATHIONE TRANSFERASE; METHIONINE; PROTEIN BCL 2; PROTEIN P28; THIOL;

ANGIOGENESIS; ANIMAL CELL; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CANCER RESISTANCE; CATALYSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STIMULATION; CELL STRAIN LY-AR; CELL STRAIN LY-AS; CELL SURVIVAL; CELL TYPE; CONTROLLED STUDY; CULTURE MEDIUM; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG EXPOSURE; DRUG MECHANISM; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TRANSFORMATION; ENZYME ACTIVITY; LYMPHOMA CELL; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; RADIOSENSITIVITY; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; THERAPY RESISTANCE;

ANIMALS; APOPTOSIS; ARSENICALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; CLONING, MOLECULAR; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; GLUTATHIONE; GLUTATHIONE TRANSFERASE; HUMANS; LYMPHOMA, B-CELL; MEMBRANE POTENTIALS; MICE; MITOCHONDRIA; OXIDES;

EID: 18744379482     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0920-0     Document Type: Article

References (44)

1. Agarwal R, Kaye SB (2003) Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 7:502
2. Anderson KC, Boise LH, Louie R, Waxman S (2002) Arsenic trioxide in multiple myeloma: rationale and future directions. Cancer J 8:12
3. Board PG, Coggan M, Chelvanayagam G, Easteal S, Jermiin LS, Schulte GK, Danley DE, Hoth LR, Griffor MC, Kamath AV, Rosner MH, Chrunyk BA, Perregaux DE, Gabel CA, Geoghegan KF, Pandit J (2000) Identification, characterization, and crystal structure of the omega class glutathione transferases. J Biol Chem 275:24798
4. 3 induces NB4 cell apoptosis with down regulation of bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 88:1052
5. Chen GQ, Zhou L, Styblo M, Walton F, Jing Y, Weinberg R, Chen Z, Waxman S (2003) Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells. Cancer Res 63:1853
6. Chiou HY, Chiou ST, Hsu YH, Chou YL, Chin-Hsiao Tseng CH, Wei ML, Chen CJ (2001) Incidence of transitional cell carcinoma and arsenic in drinking water: a follow-up study of 8,102 residents in an arseniasis-endemic area in Northeastern Taiwan. Am J Epidemiol 153:411
7. Dai J, Weinberg RS, Waxman S, Jing Y (1999) Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 93:268
8. Davison K, Cote S, Mader S, Miller WH (2003) Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines. Leukemia 5:931
9. Ding HF, Fisher DE (2002) Induction of apoptosis in cancer: new therapeutic opportunities. Ann Med 34:451
10. Ehmann UK, Nagasawa H, Petersen DF, Lett JT (1974) Symptoms of X-ray damage to radiosensitive mouse leukemic cells: asynchronous populations. Radiat Res 6:453
11. Gartenhaus RB, Prachand SN, Paniaqua M, Li Y, Gordon LI (2002) Arsenic trioxide cytotoxicity in steroid and chemotherapy-resistant myeloma cell lines: enhancement of apoptosis by manipulation of cellular redox state. Clin Cancer Res 8:566
12. Hirano S, Cui X, Li S, Kanno S, Kobayashi Y, Hayakawa T, Shraim A (2003) Difference in uptake and toxicity of trivalent and pentavalent inorganic arsenic in rat heart microvessel endothelial cells. Arch Toxicol 77:305
13. Hissin PJ, Hilf R (1976) A fluorimetric method for determination of oxidized and reduced glutathione in tissues. Anal Biochem 74:214
14. Hu XM, Hirano T, Oka K (2003) Arsenic trioxide induces apoptosis in cells of MOLT-4 and its daunorubicin-resistant cell line via depletion of intracellular glutathione, disruption of mitochondrial membrane potential and activation of caspase-3. Cancer Chemother Pharmacol 52:47
15. Jones DP (2002) Redox potential of GSH/GSSG couple: assay and biological significance. Methods Enzymol 348:93
16. Kala SV, Neely MW, Kala G, Prater CI, Atwood DW, Rice JS, Lieberman MW (2000) The MRP2/cMOAT transporter and arsenic-glutathione complex formation are required for biliary excretion of arsenic. J Biol Chem 275:33404
17. Kala SV, Kala G, Prater CI, Sartorelli AC, Lieberman MW (2004) Formation and urinary excretion of arsenic triglutathione and methylarsenic diglutathione. Chem Res Toxicol 17:243
18. Kodym R, Calkins P, Story M (1999) The cloning and characterization of a new stress response protein. A mammalian member of a family of theta class glutathione S-transferase-like proteins. J Biol Chem 274:5131
19. Kurland JF, Kodym R, Story MD, Spurgers KB, McDonnell TJ, Meyn RE (2001) NF-kappaB1 (p50) homodimers contribute to transcription of the bcl-2 oncogene. J Biol Chem 276:45380
20. Larochette N, Decaudin D, Jacotot E, Brenner C, Marzo I, Susin SA, Zamzami N, Xie Z, Reed J, Kroemer G (1999) Arsenite induces apoptosis via a direct effect on the mitochondrial permeability transition pore. Exp Cell Res 249:413
21. Liu SX, Athar M, Lippai I, Waldren C, Hei TK (2001) Induction of oxyradicals by arsenic: implication for mechanism of genotoxicity. Proc Natl Acad Sci U S A 98:1643
22. Makin G, Dive C (2003) Recent advances in understanding apoptosis: new therapeutic opportunities in cancer chemotherapy. Trends Mol Med 6:251
23. Mattern J (2003) Drug resistance in cancer: a multifactorial problem. Anticancer Res 2C:1769
24. Mirkovic N, Voehringer DW, Story MD, McConkey DJ, McDonnell TJ, Meyn RE (1997) Resistance to radiation-induced apoptosis in bcl-2-expressing cells is reversed by depleting cellular thiols. Oncogene 15:1461
25. Nguyen JT, Wells JA (2003) Direct activation of the apoptosis machinery as a mechanism to target cancer cells. Proc Natl Acad Sci U S A 100:7533
26. Sakurai T, Qu W, Sakurai MH, Waalkes MP (2002) A major human arsenic metabolite, dimethylarsinic acid, requires reduced glutathione to induce apoptosis. Chem Res Toxicol 5:629
27. Schmitt CA, Lowe SW (2002) Apoptosis and chemoresistance in transgenic cancer models. J Mol Med 80:137
28. Schwerdtle T, Walter I, Mackiw I, Hartwig A (2003) Induction of oxidative DNA damage by arsenite and its trivalent and pentavalent methylated metabolites in cultured human cells and isolated DNA. Carcinogenesis 24:967
29. Shao W, Fanelli M, Ferrara FF, Riccioni R, Rosenauer A, Davison K, Lamph WW, Waxman S, Pelicci PG, Lo Coco F, Avvisati G, Testa U, Peschle C, Gambacorti-Passerini C, Nervi C, Miller WH Jr (1998) Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. J Natl Cancer Inst 90:124
30. Smith AH, Goycolea M, Haque R, Biggs ML (1998) Marked increase in bladder and lung cancer mortality in a region of Northern Chile due to arsenic in drinking water. Am J Epidemiol 147:660
31. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, Corso D, DeBlasio A, Gabrilove J, Scheinberg DA, Pandolfi PP, Warrell RP Jr (1998) Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 339:1341
32. Steinmaus C, Moore L, Hopenhayn-Rich C, Biggs ML, Smith AH (2000) Arsenic in drinking water and bladder cancer. Cancer Invest 18:174
33. Story MD, Voehringer DW, Stephens LC, Meyn RE (1993) L-Asparaginase kills lymphoma cells by apoptosis. Cancer Chemother Pharmacol 32:129
34. Story MD, Voehringer DW, Malone CG, Hobbs ML, Meyn RE (1994) Radiation-induced apoptosis in sensitive and resistant cells isolated from a mouse lymphoma. Int J Radiat Biol 66:659
35. Story MD, Mirkovic N, Hunter N, Meyn RE (1999) Bcl-2 expression correlates with apoptosis induction but not tumor growth delay in transplantable murine lymphomas treated with different chemotherapy drugs. Cancer Chemother Pharmacol 44:367
36. Story MD, Meyn RE (1999) Modulation of apoptosis and enhancement of chemosensitivity by decreasing cellular thiols in a mouse B-cell lymphoma cell line that overexpresses bcl-2. Cancer Chemother Pharmacol 44:362
37. Vlachaki MT, Meyn RE (1998) ASTRO research fellowship: the role of BCL-2 and glutathione in an antioxidant pathway to prevent radiation-induced apoptosis. Int J Radiat Oncol Biol Phys 42:185
38. Wang TS, Kuo CF, Jan KY, Huang H (1996) Arsenite induces apoptosis in Chinese hamster ovary cells by generation of reactive oxygen species. J Cell Physiol 169:256
39. Warrell PJ, Rafii S (2000) Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood 96:1525
40. Waxman S, Anderson KC (2001) History of the development of arsenic derivatives in cancer therapy. Oncologist 6 [Suppl 2]:3
41. Yang CH, Kuo ML, Chen JC, Chen YC (1999) Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells. Br J Cancer 81:796
42. V reductase. Chem Res Toxicol 12:1278
43. Zakharyan RA, Sampayo-Reyes A, Healy SM, Tsaprailis G, Board PG, Liebler DC, Aposhian HV (2001) Human monomethylarsonic acid (MMA(V)) reductase is a member of the glutathione-S-transferase superfamily. Chem Res Toxicol 8:1051
44. Zhang P, Wang SY, Hu LH, Shi FD, Qui FD, Hong RJ, Han XY (1996) Arsenic trioxide treated 72 cases of acute promyelocytic leukemia. Chin J Hematol 17:58